Medically reviewed by David Ozeri, MD C3G (Complement 3 Glomerulopathy) and IC-MPGN (Immune Complex Membranoproliferative ...

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative ...

The FDA has approved Empaveli for the treatment of adult and pediatric patients aged 12 years and older with C3G or primary ...

I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

DelveInsight's“ IC-MPGN – Market Insights, Epidemiology, and Market Forecast – 2034 ” delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns ...

Positive results from phase 3 study of pegcetacoplan for C3G and IC-MPGN. Re-examination for approval in European markets. Find out why APLS stock is a Buy.

Waltham, Massachusetts Wednesday, July 30, 2025, 11:00 Hrs [IST] ...